Phase 4 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with relapsing-remitting multiple sclerosis (a type of MS where symptoms come and go in episodes)
- People who have not previously taken the medication fingolimod and are about to start it for the first time based on their doctor's decision and in line with the approved prescribing guidelines in Taiwan
Who may not be able to join:
- People who have been diagnosed with neuromyelitis optica (a different condition that affects the spinal cord and optic nerves)
- People who are currently taking part in another clinical trial involving an experimental treatment
- People who have had a heart attack, unstable chest pain, stroke, mini-stroke, or serious heart failure requiring a hospital stay in the past 6 months
- People who have a history of certain types of heart rhythm problems (specific types of electrical signalling issues in the heart), unless they have a working pacemaker (confirm with trial site)
- People whose heart's electrical activity, measured by an ECG, shows a reading at or above a certain threshold known as a QTc interval of 500 msec (confirm with trial site)
- People who need specific types of medication (Class Ia or Class III drugs) to control an irregular heartbeat
- People who have a known weakened immune system, a higher-than-normal risk of unusual infections, a severe active infection, or a long-lasting active infection
- People who have a serious active cancer, except for a common and usually less serious type of skin cancer called basal cell carcinoma
- People who have severe liver problems
- People who are pregnant or breastfeeding, or people of childbearing potential who are not using contraception
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Adverse Events of Special Interest(AESI); Number of Adverse Events of Special Interest (AESI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.